Encompass Health Corporation (EHC) Stock Price & How to Invest

Last updated November 2026

Short answer

Encompass Health (NYSE: EHC) is the largest US operator of inpatient rehabilitation hospitals, running about 178 facilities that treat stroke, hip fracture and brain injury patients after they leave an acute-care hospital. It is owned as a capacity-driven, Medicare-funded compounder, and you can invest in it by buying the common shares through any brokerage account. As of October 16, 2026 the shares closed near $128, up about 20% year to date and close to a 52-week high, with Q3 results due October 28.

EHC stock price

As of 2026-11-16, Encompass Health Corporation (EHC) last closed at $142.11, up 26.9% over the past year. Over the past 52 weeks it has traded between $93.83 and $142.51.

EHC last close
$142.11
1 day
+0.79%
1 month
+11.14%
1 year
+26.88%
52-week range
$93.83 to $142.51
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Encompass Health Corporation's investor relations page. Walnut is informational, not investment advice.

EHC key stats

At $142.11 on November 16, 2026, Encompass Health Corporation (EHC) has a market cap of $13.9B, a P/E of 22.7 on trailing earnings (20.6 on forward earnings) and a dividend yield of 0.59%.

Market cap
$13.9B
P/E (trailing)
22.7
P/E (forward)
20.6
EPS (trailing 12 months)
$6.25
Price to book
5.2
Dividend yield
0.59%
Beta
0.67

Market cap, P/E and yield are measured at the $142.11 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Encompass Health Corporation (EHC)?

The last two weeks for Encompass Health Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • EHC closed at $142.11 on November 16, 2026, up 0.7% over the past five trading days (from $141.15).
  • On November 6, 2026, Encompass Health Corporation filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 3, 2026, Encompass Health Corporation filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Encompass Health Corporation (EHC) latest quarter

Encompass Health reported revenue of $1.6 billion for Q3 2026, up 9% from a year earlier (Encompass Health, Oct 28, 2026).

Revenue
$1.6 billion
up 9% from a year earlier
Diluted EPS (GAAP)
$1.51
up 22% from a year earlier
Medicare
$1.1 billion
up 13% from a year earlier

Source: Encompass Health Q3 2026 results, Oct 28, 2026. Full earnings breakdown

What does Encompass Health Corporation (EHC) do?

Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. As of the second quarter of 2026 it operated 176 hospitals (about 178 by October 2026) across 39 states and Puerto Rico, which makes it the largest operator in the category by a wide margin. Medicare fee-for-service is its dominant payer, and under the IRF prospective payment system it is paid a set amount per discharge based on the patient's condition and complexity, so revenue is essentially discharges multiplied by net revenue per discharge. A portion of its hospitals are structured as joint ventures with acute-care health systems, which brings referral flow and shared construction capital while handing a slice of consolidated profit to noncontrolling interests. The company became a pure-play rehabilitation operator in 2022 when it spun off its home health and hospice arm as Enhabit.

The investment picture is unusually mechanical for a healthcare name. Second-quarter 2026 revenue was about $1.60 billion, up 9.6 percent, with adjusted EBITDA of roughly $348 million and adjusted earnings per share of about $1.55. Discharges rose 5.6 percent while same-store discharges rose 2.8 percent, so a little under half the volume growth came from capacity that did not exist a year ago. Management raised full-year 2026 guidance to $6.41 billion to $6.49 billion of revenue, $1.365 billion to $1.395 billion of adjusted EBITDA, and adjusted EPS of $6.02 to $6.25. As of October 16, 2026 the shares closed near $128 for a market capitalization near $12.6 billion, about 21 times the midpoint of guided adjusted earnings and about 19 times the 2027 consensus. The stock is up about 20 percent in 2026 but only about 4 percent over one year, because the 52-week range includes the post-2025 low near $93. What the multiple is really pricing is whether the new-hospital pipeline keeps converting, whether annual Medicare rate updates stay ahead of wage inflation, and how much of the patient pool Medicare Advantage plans redirect to cheaper post-acute settings.

Since the second-quarter report the build-out has continued. On October 6, 2026 Encompass opened a 50-bed hospital in Bangor, its first wholly owned hospital in Maine, and in September it announced its first small-format hospital: a 24-bed satellite in Conroe, Texas, expected to open in late 2027 and run off the existing hospital in The Woodlands. The company's 2026 plan now calls for eight new hospitals totaling 389 beds plus 150 to 200 beds added to existing sites. Q2 adjusted EPS of $1.55 beat the roughly $1.48 consensus, the fourth beat in a row, and third-quarter results are scheduled for October 28, with consensus near $1.36 of EPS on about $1.60 billion of revenue.

What's driving Encompass Health Corporation (EHC)?

1. De novo hospitals and bed additions

Growth here is physical, not promotional. Through the first half of 2026 Encompass opened three hospitals totaling 139 beds and added 54 beds to existing facilities, with five more hospitals and roughly 100 to 150 additional beds planned before year-end. Beds bolted onto an existing hospital carry high incremental margins because the fixed overhead is already paid for, while a brand-new hospital loses money for several quarters before it ramps. The 2026 plan totals eight new hospitals and 389 beds, including the 50-bed Bangor, Maine hospital opened October 6, 2026. A newer lever is the small-format satellite: a 24-bed hospital in Conroe, Texas, due in late 2027, will share management, referrals and payer contracts with the parent hospital in The Woodlands, a lighter way to reach nearby growth markets.

2. Demographics against a supply-constrained niche

The patient pool grows with the over-75 population, and stroke and fracture volumes track it closely. Building a competing IRF is slow: certificate-of-need laws apply in some states, Medicare's 60 percent rule constrains what kind of patients a facility can admit, and the clinical staffing model is hard to assemble. That combination limits how quickly supply can respond to demand in any given market.

3. Administered pricing that has been keeping up

The Medicare fee-for-service rate is set by CMS rather than negotiated. For fiscal 2027 CMS finalized a 2.3 percent IRF payment update, a 3.2 percent market basket less a 0.9 point productivity adjustment, which took effect in October 2026. Encompass has also been growing net revenue per discharge faster than that, about 3.9 percent in the second quarter, largely on higher patient acuity and mix.

4. Labor is the binding constraint

Nurses and therapists, not construction, decide how fast a hospital opens and how full it runs. Salaries and benefits were about $820 million in the second quarter, a little over half of revenue, so a point of wage inflation matters more than almost anything else on the income statement. Management tracks employees per occupied bed as the productivity measure, and the joint-venture partners often help with local recruiting.

What are the risks to Encompass Health Corporation (EHC)?

Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026. Finally, the balance sheet carries about $2.84 billion of debt against little cash, and capital spending on new hospitals kept trailing free cash flow to about $230 million on $1.21 billion of operating cash flow, so the build-out depends on continued access to financing.

What is the Encompass Health Corporation (EHC) forecast?

12 analysts publish price targets on EHC, averaging $156.08 as of November 2026, or +9.8% against the $142.11 share price on November 16, 2026. The published targets run from $142.00 to $177.00, a narrow spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is EHC a buy or a sell?

We give no verdict on Encompass Health Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. De novo hospitals and bed additions. Growth here is physical, not promotional. The most optimistic published target, $177.00, assumes this works close to its best case.

The case against. Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. The most pessimistic target, $142.00, is roughly what EHC is worth if this bites instead.

Read the full bull and bear case on EHC, including what would have to change to break either one. Walnut is not an investment adviser.

Has Encompass Health Corporation (EHC) split its stock?

Yes. Encompass Health Corporation (EHC) has had one share split in the last 10 years:

  • 1257:1000 on July 1, 2022, so every share held became 1.257 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of EHC the day before the 1257:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

How is Encompass Health Corporation (EHC) valued?

Market cap, P/E and dividend yield at today's price are in the EHC key stats above. The business figures below come from Encompass Health Corporation's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$6.21B
  • Q2 2026 revenue: ~$1.60B, up ~9.6%
  • Q2 2026 adjusted EPS: ~$1.55 (est. ~$1.48)
  • Net income (TTM): ~$604M (~10% margin)
  • FY2026 adjusted EBITDA guidance: ~$1.365B to $1.395B

As of October 2026: As of October 16, 2026 the shares traded near $128, giving a market capitalization around $12.6 billion against trailing revenue of roughly $6.21 billion. Guided 2026 adjusted EPS of $6.02 to $6.25 puts the stock at about 21 times the midpoint and about 19 times the 2027 consensus of $6.68, a premium to most hospital operators and a reflection of the visible bed pipeline rather than of any margin inflection. The stock has risen about 14 percent in three months to near a 52-week high, so the October 28 report arrives with less valuation cushion than in August.

Who competes with Encompass Health Corporation (EHC)?

Inpatient rehabilitation operators

Select Medical, Lifepoint Rehabilitation and Vibra Healthcare are the main for-profit competitors, alongside rehabilitation units owned outright by nonprofit health systems. Encompass is the largest by hospital count and is usually the partner of choice when an acute-care system wants a joint venture rather than its own rehabilitation build.

Alternative post-acute settings

Skilled nursing operators such as Ensign Group and PACS Group, and home health companies including Enhabit (spun off from Encompass in 2022), Addus HomeCare and UnitedHealth's Amedisys and LHC units. These are the cheaper settings Medicare Advantage plans steer toward, so they compete for the same discharge rather than for the same real estate.

Diversified hospital operators

HCA Healthcare, Tenet Healthcare and Universal Health Services control the acute-care beds that generate rehabilitation referrals and in some markets run rehabilitation capacity themselves. They are simultaneously the referral source, the potential joint-venture partner, and the alternative if a system decides to keep the patient in-house.

What stocks are similar to Encompass Health Corporation (EHC)?

Other names that sit close to EHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Encompass Health Corporation (EHC)

There are three common ways to get EHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Encompass Health Corporation (EHC)

EHC is a steady Medicare business whose value rests on opening hospitals and adding beds faster than labor costs and reimbursement policy can erode the margin on them. With the stock near a 52-week high at about 19x forward earnings, the October 28 report needs to show the pipeline still converting.

More on Encompass Health Corporation (EHC)

Whether EHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EHC a buy or a sell?, and where the stock could go from here in the EHC stock forecast.

For income investors, whether EHC pays a dividend and how the payout looks is covered in does EHC pay a dividend? And to weigh EHC against a peer, read the full side-by-side comparisons: EHC vs ADUS and EHC vs UNH.

Wondering how EHC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Encompass Health Corporation

Ask Walnut's AI anything about EHC and see how it fits what you own.

FAQ

What does Encompass Health do?

+

It operates inpatient rehabilitation hospitals, 176 of them across 39 states and Puerto Rico as of mid-2026 and about 178 by October 2026. Patients arrive after a stroke, hip fracture, brain or spinal cord injury, or major surgery, and receive intensive physician-supervised therapy before returning home. Medicare is the dominant payer, and Encompass is the largest operator in this category in the United States.

What is an inpatient rehabilitation facility?

+

An IRF is a hospital-level setting for patients who need intensive rehabilitation, generally around three hours of therapy a day, under daily physician oversight and 24-hour rehabilitation nursing. It sits between an acute-care hospital and home. Medicare pays IRFs under their own prospective payment system, a fixed amount per discharge set by the patient's condition, age and complexity rather than by length of stay.

What is the Medicare 60 percent rule?

+

It requires that at least 60 percent of a rehabilitation hospital's patients have one of 13 qualifying conditions, including stroke, hip fracture, brain injury, spinal cord injury and amputation. A facility that stays above the threshold is paid under the IRF system. One that falls below is paid as a general acute-care hospital instead, which is a materially worse rate, so compliance is managed closely.

How does Encompass Health make money?

+

Revenue is discharges multiplied by net revenue per discharge. In the second quarter of 2026 that was 68,895 discharges at about $22,521 each, producing roughly $1.60 billion. Rates for Medicare fee-for-service patients are set annually by CMS rather than negotiated, and CMS finalized a 2.3 percent update for fiscal 2027. Commercial and Medicare Advantage rates are negotiated separately and generally pay less.

How do I invest in EHC stock?

+

EHC trades on the New York Stock Exchange, so you can buy shares through any standard brokerage account. Walnut is not an investment adviser and does not tell you whether to buy it. What Walnut does is let you group a position like this under a stated thesis, such as aging demographics or post-acute care, and track how it performs against that idea.

How fast is Encompass Health growing?

+

Second-quarter 2026 revenue rose 9.6 percent and adjusted EPS rose about 10.7 percent. Discharges grew 5.6 percent while same-store discharges grew 2.8 percent, so roughly half the volume came from new capacity. The company opened three hospitals and added 54 beds in the first half, with five more hospitals and 100 to 150 beds planned before year-end 2026. The full 2026 plan is eight new hospitals totaling 389 beds, including the 50-bed Bangor, Maine hospital opened in October 2026.

What is the Encompass Health class action about?

+

In July 2025 The New York Times published an article on readmission rates at for-profit rehabilitation hospitals, citing Medicare data, and the stock fell about 10 percent that day. Several plaintiff law firms subsequently announced securities investigations. A separate ERISA class action concerning the company's retirement plan was filed in March 2026. Investigations are solicitations, not filed securities complaints, so check current filings before drawing conclusions.

What are the biggest risks to EHC?

+

Concentration in a single, regulated payer is the main one: any move toward site-neutral payment between rehabilitation hospitals and skilled nursing would hit revenue directly. Medicare Advantage growth diverts patients to cheaper settings and adds authorization friction. Salaries and benefits run a little over half of revenue, so wage inflation compresses margins fast, and new hospitals can be delayed by construction or staffing.

How has EHC stock performed in 2026?

+

As of the October 16, 2026 close near $127.92, EHC was up about 20% year to date and about 14% over three months, near the top of its 52-week range of roughly $93 to $130. Over one year the gain is about 4%. The average analyst target is about $148 across 12 analysts, and William O'Neill initiated coverage with a Buy rating in October 2026.

Does Encompass Health pay a dividend?

+

Yes. Encompass pays $0.84 a share a year, a yield of about 0.7% as of October 2026 with a payout ratio near 13%. Most cash goes into building new hospitals and beds, so the dividend is a small part of the return.

What is Encompass Health's small-format hospital?

+

In September 2026 Encompass announced its first small-format inpatient rehabilitation hospital, a 24-bed facility in Conroe, Texas, expected to open in late 2027. It will operate as a satellite of the company's hospital in The Woodlands, sharing management, referral relationships and payer contracts, which lets Encompass add capacity in nearby growth markets with a lighter footprint.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Encompass Health Corporation's investor relations page or your broker before making investment decisions.